One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.
The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer is “no,” according to follow-up information provided.
Analyst Salveen Richter and colleagues laid it out:
Source: FS – All – Science – News
“Is curing patients a sustainable business model?” Goldman Sachs analysts ask